Shaanxi Cuikang Pharmaceutical Technology Co., Ltd

Viggliptin is a selective, competitive and reversible DPP24 inhibitor. Glucose-dependent insulin-promoting polypeptide (GIP) and glucagon-like polypeptide 21 (GLP21) are important hormones that maintain glucose concentration in the body, and both have the effect of incretin. In patients with type 2 diabetes, GIP's insulin stimulating effect is impaired. Only GLP21 can play the role of insulin stimulating hormone secretion by acting on the islets β The receptor on the cell membrane promotes the secretion of insulin. GLP21 can also inhibit the secretion of glucagon and gastric emptying, thus increasing satiety (inhibiting appetite). DPP24 combines with protein in many tissues, such as the brush edge of kidney, liver, small intestine membrane, pancreatic duct, lymphocytes, and endothelial cells. It can rapidly inactivate GLP21 by hydrolyzing the second alanine at the N-terminal. This product inhibits the activity of the enzyme by combining with DPP24 to form DPP24 complex, which increases the concentration of GLP21 and promotes the islet β When cells produce insulin, they reduce the concentration of glucagon, thereby lowering blood sugar. There was no significant effect on body weight.